Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 90 days matching "european medicines"

Drug approvalEMAYesterday

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2026

The European Medicines Agency approved eight new medicines in May 2026. The article mentions a few specific drugs, including Jascayd (nerandomilast) and Boey (trenibotulinumtoxinE), though details about what diseases they treat are incomplete in this announcement.

WHY IT MATTERSIf you have a rare disease, one of these eight newly approved medicines might be a treatment option available in Europe — check with your doctor to see if any match your condition.
💬 Ask your doctor
PolicyEMAMay 12

EMA actively monitoring cruise ship Hantavirus outbreak

The European Medicines Agency (EMA) is closely watching an outbreak of Andes hantavirus that started on a cruise ship. Hantavirus is a serious infection spread by infected rodents that can cause severe lung and kidney problems in people. The EMA is working with other European health organizations to monitor the situation and make sure patients get proper treatment.

WHY IT MATTERSIf you or a family member traveled on the affected cruise ship or have symptoms like fever, muscle aches, and difficulty breathing, this outbreak alert helps you understand your potential exposure risk and when to seek medical care.
💬 Ask your doctorAndes hantavirus infection
Drug approvalRSSApr 28

EU panel recommends expanded use of DMD treatment Agamree

A European health committee has recommended that Agamree, a medicine for Duchenne muscular dystrophy (DMD), be approved for use in younger children starting at age 2. Previously, the drug was approved for older children and adults. This recommendation means more DMD patients in Europe could potentially access this treatment if the European Medicines Agency approves the committee's suggestion.

WHY IT MATTERSThis expanded approval could allow children with DMD as young as age 2 to start Agamree treatment earlier, potentially slowing muscle weakness progression during critical early development years.
💬 Ask your doctorDuchenne muscular dystrophy

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases